Ovarian Cancer

Caelyx Cancer Treatment Receives Approval in Canada

Published in Women's Health Weekly, March 1st, 2001

A drug treatment developed at the University of Alberta (U of A) to improve the quality of life for women with ovarian cancer has been approved for use in Canada.

"This approval means these women now have a chance of therapy that appears to be useful," said Dr. Terry Allen, a U of A pharmacology professor who developed the treatment. "Every year, 2,500 women in Canada are diagnosed with ovarian cancer and of that number 1,500 will die. Those are the women we are targeting, the ones who would die or are at the advanced stages of the disease."

Schering Canada announced that Health Canada has approved Caelyx, the brand name for liposomal doxorubicin,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2001-03-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry